Bangkok Genomics Innovation PCL (BKK:BKGI) PE Ratio (TTM): 26.93 (As of Jul. 26, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:BKGI Bangkok Genomics Innovation PCL BKK:BKGI
45 GF Score
Price ฿2.02
! 12 Warning Signs
View Full Analysis

What is Bangkok Genomics Innovation PCL PE Ratio (TTM)?

Bangkok Genomics Innovation PCL BKK:BKGI +1.51% 45 PE Ratio (TTM) is 26.93 as of Jul. 26, 2026, which is 1% below its 10-year median of 27.20. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 58.51% on this metric.

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-26), Bangkok Genomics Innovation PCL's share price is ฿2.02. Bangkok Genomics Innovation PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ฿0.08. Therefore, Bangkok Genomics Innovation PCL's PE Ratio (TTM) for today is 26.93.


The historical rank and industry rank for Bangkok Genomics Innovation PCL's PE Ratio (TTM) or its related term are showing as below:

BKK:BKGI' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 16.53   Med: 27.2   Max: 86.51
Current: 26.93


During the past 7 years, the highest PE Ratio (TTM) of Bangkok Genomics Innovation PCL was 86.51. The lowest was 16.53. And the median was 27.20.


BKK:BKGI's PE Ratio (TTM) is ranked better than
58.51% of 94 companies
in the Medical Diagnostics & Research industry
Industry Median: 32.575 vs BKK:BKGI: 26.93

Bangkok Genomics Innovation PCL's Earnings per Share (Diluted) for the three months ended in Dec. 2025 was ฿0.04. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ฿0.08.

As of today (2026-07-26), Bangkok Genomics Innovation PCL's share price is ฿2.02. Bangkok Genomics Innovation PCL's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was ฿0.08. Therefore, Bangkok Genomics Innovation PCL's PE Ratio without NRI for today is 26.93.

During the past 7 years, Bangkok Genomics Innovation PCL's highest PE Ratio without NRI was 86.51. The lowest was 16.53. And the median was 27.20.

Bangkok Genomics Innovation PCL's EPS without NRI for the three months ended in Dec. 2025 was ฿0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was ฿0.08.

During the past 12 months, Bangkok Genomics Innovation PCL's average EPS without NRI Growth Rate was -13.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was -15.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.10% per year.

During the past 7 years, Bangkok Genomics Innovation PCL's highest 3-Year average EPS without NRI Growth Rate was 32.90% per year. The lowest was -20.60% per year. And the median was -15.30% per year.

Bangkok Genomics Innovation PCL's EPS (Basic) for the three months ended in Dec. 2025 was ฿0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was ฿0.08.


Bangkok Genomics Innovation PCL  (BKK:BKGI) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Bangkok Genomics Innovation PCL PE Ratio (TTM) Related Terms


Bangkok Genomics Innovation PCL PE Ratio (TTM) Historical Data

* Premium members only.

The historical data trend for Bangkok Genomics Innovation PCL's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL PE Ratio (TTM) Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio (TTM)
Get a 7-Day Free Trial N/A N/A N/A 25.00 16.45

Bangkok Genomics Innovation PCL Quarterly Data
Dec19 Dec20 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.00 27.46 21.55 31.60 16.45

BKK:BKGI vs TMO, DHR, IDXX: PE Ratio (TTM) Comparison

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bangkok Genomics Innovation PCL PE Ratio (TTM) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's PE Ratio (TTM) falls into.


BKK:BKGI
45GF Score
Bangkok Genomics Innovation PCL BKK:BKGI
PE Ratio (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bangkok Genomics Innovation PCL PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Bangkok Genomics Innovation PCL's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=2.02/0.075
=26.93

Bangkok Genomics Innovation PCL's Share Price of today is ฿2.02.
Bangkok Genomics Innovation PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.08.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio (TTM) →
What does a PE Ratio (TTM) of 26.93 mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a PE Ratio (TTM) of 26.93 as of Jul. 26, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is near median its historical median of 27.20. Over the past decade, Bangkok Genomics Innovation PCL's PE Ratio (TTM) has ranged from 16.53 to 86.51. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #39 out of 94 companies in the Medical Diagnostics & Research industry, placing it in the top 41.5%.
Is Bangkok Genomics Innovation PCL's PE Ratio (TTM) too high?
Bangkok Genomics Innovation PCL's current PE Ratio (TTM) of 26.93 is near median its 10-year median of 27.20. Over the past 10 years, this metric has ranged from a low of 16.53 to a high of 86.51. The Medical Diagnostics & Research industry median PE Ratio (TTM) is 32.58. Bangkok Genomics Innovation PCL's value of 26.93 is 17.3% below this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #39 out of 94 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's PE Ratio (TTM) compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #39 out of 94 companies for PE Ratio (TTM). This puts Bangkok Genomics Innovation PCL in the upper half of its industry. The industry median PE Ratio (TTM) is 32.58. Bangkok Genomics Innovation PCL's value of 26.93 is 17.3% below this benchmark. Historically, Bangkok Genomics Innovation PCL's own PE Ratio (TTM) has ranged from 16.53 to 86.51 over the past decade. While the company's 10-year median is 27.20 vs. the industry median of 32.58, Bangkok Genomics Innovation PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Diagnostics & Research company?
The median PE Ratio (TTM) among Medical Diagnostics & Research companies is 32.58, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current PE Ratio (TTM) of 26.93 is 17.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio (TTM) is 32.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current PE Ratio (TTM) is 26.93, which is near median its own 10-year median of 27.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current PE Ratio (TTM) of 26.93. The current PE Ratio (TTM) is 26.93, which is near median its 10-year median of 27.20 and 17.3% below the Medical Diagnostics & Research industry median of 32.58. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current PE Ratio (TTM) is 26.93 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bangkok Genomics Innovation PCL Business Description

Address 3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score

Get the complete analysis for BKK:BKGI

PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿2.02
Price